0 5 10 15 20 0 4 8 12 16 20 24 2.5 mg 5 mg 10 mg 60 65 70 75 80 0 4 8 12 16 20 24 2.5 mg 5 mg 10 mg 2.5 mg 13 13 13 13 13 13 13 5 mg 13 13 13 13 13 13 13 10 mg 13 13 13 13 13 12 12 The top two dose levels achieve meaningful vision gains of >10 letters by Week 4, subsequently achieving a 20/25 Snellen visual acuity by Week 20, with continued strengthening of visual acuity from week 12 to week 20 Mean ETDRS Letters Mean Change in BCVA over time Sample Size Observed BCVA over time Dose Level Preliminary Analysis 2.5 mg 13 13 13 13 13 13 13 5 mg 13 13 13 13 13 13 13 10 mg 13 13 13 13 13 12 12 Sample Size Dose Level Mean ETDRS Letters +11.8 +13.4 +15.4 The APEX study is ongoing. Final results may be different due to additional data collection or data cleaning. Includes patients in the per protocol set that completed the Week 12 visit and met all the eligibility criteria. Excludes one patient in the 5 mg dose that discontinued treatment before Week 4, and one patient in the 10 mg dose with a significant epiretinal membrane at baseline (exclusion criterion). Weeks Weeks 70